Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Atea Pharmaceuticals, Inc. (AVIR) had Normalized Income after Taxes of $-158.35M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-158.35M |
|
-- |
|
-- |
|
$180.89M |
|
$-180.89M |
|
$16.38M |
|
$-164.51M |
|
$-164.51M |
|
$-158.35M |
|
$-158.35M |
|
$-158.35M |
|
|
Normalized Income after Taxes |
$-158.35M |
$-180.89M |
|
$-185.41M |
|
81.50M |
|
81.50M |
|
$-1.94 |
|
$-1.94 |
|
| Balance Sheet Financials | |
$310.99M |
|
$0.46M |
|
$4.23M |
|
$315.22M |
|
$39.78M |
|
-- |
|
-- |
|
$39.78M |
|
$275.43M |
|
$275.43M |
|
$275.43M |
|
78.13M |
|
| Cash Flow Statement Financials | |
$-132.03M |
|
$188.79M |
|
$-25.75M |
|
$64.70M |
|
$95.71M |
|
$31.02M |
|
$20.72M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.82 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-132.03M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-57.49% |
|
-57.49% |
|
-50.23% |
|
-57.49% |
|
$3.53 |
|
$-1.62 |
|
$-1.62 |
|